North America Point-Of-Care-Testing (POCT) Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

Customize Your Report Customize Your Report Buy Now Buy Now Free Sample Report Free Sample Report
Home Healthcare North America Point Care Testing Poct Market
Request for TOC Request for TOC Speak to Analyst Speak to Analyst Free Sample Report Free Sample Report Inquire Before Buying Inquire Before Buy Now Buy Now

North America Point-Of-Care-Testing (POCT) Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

  • Healthcare
  • Apr 2025
  • North America
  • 350 Pages
  • No of Tables: 486
  • No of Figures: 42
Buy Now Buy Now Request for Sample Request for Sample
Nucleus Nucleus

Circumvent the Tariff challenges with an agile supply chain Consulting

Supply Chain Ecosystem Analysis now part of DBMR Reports

North America Point Care Testing Poct Market

Market Size in USD Billion

CAGR :  % Diagram

Bar chart comparing the North America Point Care Testing Poct Market size in 2024 - 16.29 and 2032 - 33.68, highlighting the projected market growth. USD 16.29 Billion USD 33.68 Billion 2024 2032
Diagram Forecast Period
 2025 –2032
Diagram Market Size (Base Year)
 USD 16.29 Billion
Diagram Market Size (Forecast Year)
 USD 33.68 Billion
Diagram CAGR
 %
Diagram Major Markets Players
  • Dummy1
  • Dummy2
  • Dummy3
  • Dummy4
  • Dummy5
Request For Unlock

North America Point-Of-Care-Testing (POCT) Market, By Product Type (Glucose Monitoring Products, Infectious Disease Testing Products, Cardiometabolic Monitoring Products, Pregnancy and Fertility Testing Products, Hematology Testing Products ,Coagulation Monitoring Products, Drugs-Of-Abuse (DOA) Testing Products, Urinalysis Testing Products, Cholesterol Testing Products, Tumor/Cancer Marker Testing Products, Fecal Occult Testing Products, and Others),By Platform (Lateral Flow Assays/Immunochromatography Tests, Immunoassays, Dipsticks, Molecular Diagnostics, Clinical Chemistry Assays, Microfluidics, Hematology, Others),By Application (Blood Glucose, Infectious Diseases, Vital Sign Monitoring, Cardiac Monitoring, Coagulation, Haematology, Non- Invasive SpO2 Monitoring, Blood Transfusion, Non- Invasive PCO2 Monitoring, Whole Blood Analysis, Others), By Prescription Mode (Prescription-Based Testing, and Over The Counter Testing, By End User ( Hospitals, Home Care, Clinics, Laboratories, Diagnostic Centers, Pathology Labs, Ambulatory Surgery Centers, Elderly Care Centers, Others), By Distribution Channel (Direct Tender, Retail Sales, Online Sales, and Others) - Industry Trends & Forecast To 2032

North America Point-Of-Care Testing (POCT) Market

North America Point-Of-Care Testing (POCT) Market Analysis

The North America Point-of-Care Testing (POCT) market is experiencing significant growth due to advancements in medical technology, increasing demand for rapid diagnostics, and a rise in chronic diseases. PoCT allows for quick results at the patient’s location, improving patient outcomes and reducing healthcare costs. Key drivers include the growing focus on personalized medicine, aging populations, and the convenience of home testing. Moreover, innovations in mobile health (mHealth) and wearable devices are shaping the market. North America holds the largest market share, while Asia Pacific is expected to witness the fastest growth due to rising healthcare infrastructure and demand.

North America Point-Of-Care Testing (POCT) Market Size

North America Point-Of-Care Testing (POCT) market size was valued at USD 16.29 billion 2024 and is projected to reach USD 33.68 billion by 2032, with a CAGR of 9.5% during the forecast period of 2025 to 2032. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include import export analysis, production capacity overview, production consumption analysis, price trend analysis, climate change scenario, supply chain analysis, value chain analysis, raw material/consumables overview, vendor selection criteria, PESTLE Analysis, Porter Analysis, and regulatory framework.

North America Point-Of-Care Testing (POCT) Market  Trends

“Rising Adoption of Advanced Diagnostic Technologies in the North America Point-of-Care Testing (POCT)”

The North America Point-of-Care Testing (POCT) market is experiencing significant growth, driven by advancements in diagnostic technology, increased demand for rapid testing, and the ongoing need for accessible healthcare solutions. Key trends include the rise of decentralized healthcare systems, where testing is shifting from centralized laboratories to patient-centric settings like homes, pharmacies, and clinics. The increasing adoption of mobile health devices and wearables is enabling real-time monitoring and immediate diagnostic results. Moreover, innovations in molecular and genetic testing are improving accuracy and expanding the scope of POCT to include a wider range of conditions, from infectious diseases to chronic illnesses. Regulatory support and favorable reimbursement policies are further bolstering market expansion. Additionally, the COVID-19 pandemic has accelerated the use of POCT for quick detection of viral infections, solidifying its role in public health management. As demand for quicker, more convenient diagnostic tools grows, the POCT market is expected to continue its upward trajectory, with a focus on affordability, user-friendliness, and integration with digital health platforms.

Report Scope and North America Point-Of-Care Testing (POCT) Market  Segmentation

Attributes

North America Point-Of-Care Testing (POCT) Market  Insights

Segments Covered
  • By Product Type: (Glucose Monitoring, Products, Infectious Disease Testing Products, Cardiometabolic Monitoring, Products, Pregnancy and Fertility Testing Products, Hematology Testing Products, Coagulation Monitoring Products, Drugs-Of-Abuse (DOA) Testing Products, Urinalysis Testing Products, Cholesterol Testing Products, Tumor/Cancer Marker, Testing Products, Fecal Occult Testing Products, and Others
  • By Platform: (Lateral Flow Assays/Immunochromatography Tests, Immunoassays, Dipsticks, Molecular, Diagnostics, Clinical Chemistry Assays, Microfluidics, Hematology, Others)
  • By Application: Blood Glucose, Infectious Diseases, Vital Sign Monitoring, Cardiac Monitoring, Coagulation, Haematology, Non- Invasive SpO2 Monitoring, Blood Transfusion, Non- Invasive PCO2 Monitoring, Whole Blood Analysis, Others
  • By Prescription Mode: Prescription-Based Testing, Over The Counter Testing
  • By End User: Hospitals, Home Care, Clinics, Laboratories, Diagnostic Centers, Pathology Labs, Ambulatory Surgery Centers, Elderly Care Centers, Others
  • By Distribution Channel: Direct Tender, Retail Sales, Online Sales, and Others

Region Covered

U.S., Canada, Mexico

Key Market Players

F. Hoffmann-La Roche Ltd (Switzerland), Danaher Corporation (U.S.), Siemens Healthineers AG (Germany), BD (Becton, Dickinson and Company) (U.S.), Abbott (U.S.), Pfizer Inc. (U.S.), QuantuMDx Group Ltd. (U.K.), Thermo Fisher Scientific Inc. (U.S.), Nova Biomedical (U.S.), Trividia Health, Inc. (U.S.), Sienco, Inc. (U.S.), PTS Diagnostics (U.S.), Abaxis (a part of Zoetis) (U.S.), Werfen (Spain), Binx Health (U.S.), BIOMÉRIEUX (France), QIAGEN (Germany), QuidelOrtho Corporation (U.S.), Accubiotech Co., Ltd. (China), Sekisui Diagnostics (U.S.), Trinity Biotech (Ireland), BD Veritor (BD) (U.S.), Hologic, Inc. (U.S.), Sysmex Corporation (Japan), and Meridian Bioscience (U.S.)

Market Opportunities

  • Rising Use Of Poc Testing In Healthcare Facilities
  • Rising Incidence Of Substance Abuse

Value Added Data Infosets

In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include import export analysis, production capacity overview, production consumption analysis, price trend analysis, climate change scenario, supply chain analysis, value chain analysis, raw material/consumables overview, vendor selection criteria, PESTLE Analysis, Porter Analysis, and regulatory framework.

North America Point-Of-Care Testing (POCT) Market  Definition

The North America point-of-care testing (POCT) market refers to the diagnostic testing performed at or near the site of patient care, such as homes, clinics, pharmacies, or hospitals, providing rapid and accurate results. POCT includes devices for testing a variety of conditions, ranging from infectious diseases to chronic conditions like diabetes and heart disease. The market is driven by technological advancements, including portable devices, mobile health solutions, and wearables, enabling real-time diagnostics. Growing demand for convenient, cost-effective healthcare, especially in decentralized settings, along with supportive regulatory policies, is fueling the expansion of the POCT market North Americaly.

North America Point-Of-Care Testing (POCT) Market  Dynamics

Drivers  

  • Rising Use Of Poc Testing In Healthcare Facilities

The rising use of Point-of-Care (POC) testing in healthcare facilities is revolutionizing the way healthcare providers diagnose and manage diseases. With the increasing need for quick and accurate diagnostic results, healthcare professionals are turning to POC testing to enhance patient care. This shift is particularly evident in emergency rooms, outpatient clinics, and diagnostic centres, where rapid decision-making is crucial. POC testing allows healthcare providers to obtain immediate results at the point of care, eliminating the need for patients to wait for laboratory results and significantly reducing the time to diagnosis and treatment. Furthermore, POC tests are highly portable and user-friendly, making them ideal for use in diverse healthcare settings, from rural clinics to large hospitals. The rising prevalence of chronic diseases and the growing demand for efficient healthcare solutions further fuel the adoption of POC testing, as it enables better disease monitoring, especially in conditions like diabetes, cardiovascular diseases, and infectious diseases. As healthcare facilities increasingly incorporate these technologies into their workflows, the demand for point-of-care testing continues to grow, acting as a key driver for the market's expansion.

For instance, 

  • In March 2024, according to the article published by NCBI, the rapid turnaround time of POCT enhances clinical decision-making, reduces management time, and improves triage efficiency, especially in emergency departments (EDs). Its flexibility extends to pre-hospital settings, field hospitals, and during disasters, mass gatherings, or in overcrowded areas. This widespread adoption of POCT in healthcare facilities accelerates its demand, acting as a significant driver for the North America market
  • In November 2024, according to the article published by OBJECTIVE Investment Banking & Valuation, the shift towards point-of-care testing (POCT) has revolutionized healthcare by bringing diagnostics directly to the patient care location. Its speed, convenience, and efficiency make it invaluable in emergency, outpatient, and remote settings. As the demand for rapid diagnostics grows, POCT’s integration into clinical practices drives market expansion, acting as a key catalyst for the North America market’s growth.
  • The growing adoption of Point-of-Care (POC) testing in healthcare facilities is transforming disease diagnosis and management. With the need for fast, accurate results, healthcare providers are utilizing POC testing to improve patient care. This is especially important in emergency rooms, outpatient clinics, and diagnostic centers, where timely decision-making is critical. POC testing offers immediate results, reducing wait times for lab reports and speeding up diagnosis and treatment. Its portability and ease of use make it suitable for various healthcare environments, from rural clinics to large hospitals. The rising prevalence of chronic conditions like diabetes and cardiovascular diseases, along with the demand for efficient healthcare solutions, further drives the use of POC testing, promoting better disease management and market growth. .

Rising Incidence Of Substance Abuse

The rising incidence of substance abuse worldwide has significantly contributed to the growth of the North America Point of-Care Testing (POCT) market. With the increasing number of individuals affected by substance use disorders, there is a pressing need for rapid, reliable diagnostic tools that can quickly identify substance abuse and monitor treatment effectiveness. POCT offers the advantage of providing immediate results, which is crucial for timely intervention, especially in emergency situations or when patients require urgent care. This testing method allows healthcare professionals to detect substances like alcohol, opioids, and illicit drugs in real time, facilitating more efficient decision-making and treatment strategies. Furthermore, as awareness of substance abuse issues grows, the demand for accessible and affordable testing solutions in various healthcare settings, such as clinics, addiction treatment centers, and rehabilitation facilities, continues to rise. With increasing government and public health initiatives to combat substance abuse, POCT plays a vital role in managing the crisis, driving its 235 North America Point-of-Care Testing (POCT) Market- Industry Trends and Forecast to 2032 widespread adoption and fuelling market growth.

For instance,

  • In January 2024, according to an article published by NCBI, Opioid Use Disorder (OUD) affects over 16 million people worldwide, including 2.1 million in the U.S., leading to more than 120,000 deaths North Americaly each year. The prevalence of opioid use and dependency is high, with up to 50% of long-term opioid users meeting OUD criteria. The rising incidence of opioid-related issues drives the need for effective drug testing solutions, thereby fueling growth in the North America Point-of-CARE (POC) testing market
  • In August 2023, according to an article published by WHO, in 2019, approximately 600,000 deaths North Americaly were linked to drug use, with about 80% related to opioids. Of these, around 125,000 were due to opioid overdose, while non-fatal overdoses are significantly more common. The rise in opioid overdoses is attributed to increased opioid availability for chronic pain management and the presence of potent opioids on the illicit market. In the USA, drug overdose deaths totalled 70,630 in 2019, with synthetic opioids involved in about half of these cases. From 2013 to 2019, synthetic opioid death rates in the USA surged by 1040%, with a further spike during the COVID-19 pandemic. This data underscores the "rising incidence of substance abuse" by highlighting the increasing prevalence and severity of opioid-related overdoses, which drives the demand for effective drug testing solutions.
  • In June 2020, according to the article published by ARCHIVERS of pathology & Laboratory Medicine, the opioid epidemic has created a critical demand for point-of-care (POC) drug testing, addressing significant clinical needs. While current POC tests face limitations in sensitivity and specificity, innovative solutions like microfluidics and miniature mass spectrometry are emerging. The future development of quantitative POC devices and real-time testing further propels the demand, acting as a key driver for market growth in the substance abuse sector. .

The rising North America incidence of substance abuse has significantly boosted the growth of the point-of-care testing (POCT) market. As substance use disorders become more prevalent, there is an increasing demand for fast, accurate diagnostic tools to detect and monitor substance abuse. POCT offers immediate results, enabling timely interventions in emergency situations and urgent care. It allows healthcare professionals to quickly identify substances like alcohol, opioids, and illicit drugs, improving treatment and decision-making. With greater awareness and more public health efforts to address substance abuse, the demand for accessible testing solutions in clinics and rehabilitation centres continues to grow, further driving the adoption of POCT.

  • Increased Adoption Of Telemedicine

The rapid growth of telemedicine has significantly contributed to the rise of Point-of-Care Testing (POCT), especially in the context of remote healthcare. As telehealth platforms expand, there is an increasing demand for diagnostic tools that enable healthcare providers to remotely monitor patients, conduct assessments, and provide real-time results. POCT solutions play a crucial role in this transformation, as they allow healthcare professionals to obtain accurate and timely test results without the need for patients to visit clinics or hospitals. This ability to conduct diagnostics at home or in remote areas not only enhances patient access to healthcare but also improves the efficiency of care delivery by reducing wait times and the burden on healthcare facilities. The integration of POCT with telemedicine systems facilitates seamless communication between patients and healthcare providers, ensuring timely interventions. As telemedicine continues to grow, the demand for POCT devices, which are essential for delivering rapid and reliable diagnostics in a virtual healthcare environment, becomes a key driver for the market’s expansion.

For instance,

  • In March 2024, according to the article published by DPU, Telemedicine enables remote healthcare services by connecting patients with healthcare professionals virtually, regardless of location. In point of-care testing, patients can perform self-tests or undergo tests administered locally, with results sent to specialists for analysis. This provides timely access to expert medical advice, particularly in underserved areas, driving the need for POCT solutions and fuelling market growth
  • In February 2022, according to the article published by Medical Device Network, Point-of-care diagnostics is transforming remote healthcare by offering patients, particularly those with chronic diseases, easier access to diagnostic data. This shift allows for continuous monitoring and timely interventions, even in areas with limited healthcare infrastructure. As telemedicine adoption grows, the demand for efficient and accessible POCT solutions rises, acting as a significant driver for the North America market expansion .

The rapid growth of telemedicine has boosted point-of-care testing (POCT), especially for remote healthcare. As telehealth platforms grow, the need for diagnostic tools that allow remote monitoring and real-time results has increased. POCT enables healthcare providers to obtain accurate test results without requiring patient visits, improving access to care and reducing wait times. By integrating POCT with telemedicine, communication between patients and providers is streamlined, ensuring timely interventions. As telemedicine evolves, the demand for POCT devices continues to fuel market growth.

Opportunities

  • Rising Awareness And Advocacy For Point-Of-Care Testing

The increasing awareness surrounding the importance of early diagnosis, coupled with robust public health campaigns and government support, presents a significant opportunity for growth in the North America Point-of-Care (POC) testing market. As society becomes more focused on proactive healthcare, there is a rising demand for accessible and efficient testing solutions. Public health campaigns, led by both governmental and non governmental organizations, play a crucial role in educating communities about the benefits of early detection and timely intervention. These initiatives not only raise awareness about various health conditions but also advocate for the widespread use of point-of-care testing in improving patient outcomes. Additionally, government support through funding and policy-making facilitates the adoption of POC testing technologies by establishing favorable regulatory frameworks. This encourages the implementation of these solutions across diverse settings, such as clinics, hospitals, and even remote or underserved areas. The combination of increased awareness and strategic government support creates a favorable environment for market expansion, driving innovation and broadening access to advanced testing solutions to meet the growing healthcare needs North Americaly

  • In December 2023, according to the article published by the Greater London Authority, UK government allocated USD 1.54 million to this mission, focusing on testing for 14 different drugs with the rising awareness and proactive government initiatives in the UK have led to the implementation of random mandatory drug testing for individuals released from prison, aiming to reduce crime rates. This move underscores the nation's commitment to tackling substance abuse and its impact on criminal behavior, reflecting broader efforts to enhance public safety and well-being
  • In July 2021, according to the article published by Commonwealth of Australia and the Department of Health and Aged Care, the Australian government launched the National Ice Action Strategy, which included significant investments to enhance Point-of-Care (POC) drug abuse testing. This initiative aimed to curb the growing use of methamphetamines, commonly known as "ice," by providing law enforcement and healthcare providers with more accessible and accurate drug testing tools. The strategy also focused on expanding the availability of POC testing in remote and rural areas, ensuring that communities across the country could benefit from timely and effective drug detection and intervention measures

Hence, the convergence of rising awareness, proactive public health campaigns, and strong government support is set to drive substantial growth in the North America Point-of-Care (POC) Testing Market. This dynamic environment not only accelerates the adoption of POC testing technologies but also promotes the development of more advanced, efficient, and accessible solutions. As these factors continue to evolve, the future of POC testing looks promising, with enhanced opportunities for innovation, broader market reach, and improved healthcare outcomes worldwide.

  • Strategic Initiation And Decision Taken By The Market Players

Strategic collaborations and partnerships between leading companies and research institutions are driving the development of advanced point-of-care testing (POCT) technologies and expanding market reach. These collaborations enable companies to enhance product offerings, improve accuracy, and widen their customer base. Mergers and acquisitions further strengthen the market by integrating complementary technologies and opening access to new markets. The continuous expansion of product portfolios and the introduction of innovative solutions cater to the evolving needs of sectors such as healthcare, education, and workplaces. These strategic efforts collectively fuel the growth of the POCT market, making testing more accessible, accurate, and efficient North Americaly.

For instance,

In February 2021, according to the article published by Thermo Fisher Scientific Inc.,Thermo Fisher Scientific acquired Mesa Biotech, a company specializing in POC molecular diagnostic tests. While Mesa Biotech’s primary focus was on infectious disease testing, the acquisition provided Thermo Fisher with additional capabilities in rapid POC testing, which could be leveraged to expand into drug abuse testing. This acquisition is part of Thermo Fisher’s broader strategy to enhance its POC testing offerings across various diagnostic areas

In May 2024, according to the article published by ResearchGate, the increasing demand for rapid, accurate, and accessible diagnostics presents a significant opportunity for the North America Point-of-Care Testing (POCT) Market. As healthcare systems seek more efficient alternatives to traditional laboratory testing, POCT offers the potential to enhance patient care by enabling quick results, reducing wait times, and providing convenience, especially in remote or resource-limited areas. Additionally, the integration of intelligent technologies and advancements in device sensitivity can drive innovation, improving test accuracy and expanding the range of conditions that can be diagnosed. These factors collectively create a dynamic environment for market growth and the development of more advanced, cost-effective POCT solutions

  • In August 2022, according to the news published in Healthcare Transformers, POCT presents a significant opportunity for North America healthcare by enhancing accessibility, particularly in underserved areas. With growing demand for rapid, cost-effective diagnostics, mobile units and community-based solutions offer efficient care. POCT's potential to reduce healthcare costs, improve early disease detection, and alleviate hospital burdens drives market expansion and innovation

In conclusion, the strategic decisions and initiatives by key players are crucial in fostering growth within the point of-care testing industry. As companies invest in collaborations, mergers, and portfolio expansions, they will benefit from enhanced technological advancements and increased product availability. These efforts will meet the rising demand for rapid and accurate diagnostics, improving healthcare outcomes and supporting more efficient patient care across various sectors.

  • Expanding Product Range For Point-Of-Care Testing

The growing variety of product options for Point-of-Care (POC) drug testing presents a significant opportunity for expansion. As the need for rapid, accurate, and convenient drug testing increases, manufacturers are broadening their offerings to include single-drug test strips, multi-drug cassettes, dip cards, and cups. This diverse range of products caters to different testing requirements, from simple at-home screenings to more detailed multi-drug assessments in clinical and workplace environments. By diversifying their product lines, companies can meet a broader range of user needs, enhance accessibility, and address varying levels of complexity and sensitivity in drug detection. This trend not only supports the rising demand for efficient drug testing solutions but also fosters innovation and competition, leading to technological advancements and improved testing accuracy and reliability.

For instance-

  • In January 2025, according to the research published by ScienceDirect, the article discusses advancements in point-of-care testing (POCT), focusing on one-step lateral flow and microfluidic assays for home testing. Key areas include signal amplification, assay design, and sample preparation, aiming to reduce user intervention. It emphasizes overcoming challenges in commercialization, ensuring cost-effective, reliable, and accessible diagnostic solutions
  • In December 2023, according to the research published by Healgen, company has a diverse range of products, including Single-Drug Test Strips, Cassettes, and Dip Cards, as well as Multi-Drug Test Cassettes, Dip Cards, and Cups. This extensive product lineup caters to various testing needs and settings, from simple at-home tests to more comprehensive multi-drug screenings

The expansion of product types in the North America point-of-care (POC) testing market is set to drive significant growth and innovation. As the market evolves to meet diverse user needs and integrates advancements in technology, a wider array of testing solutions will enhance diagnostic efficiency and accuracy. This increased product diversity 241 North America Point-of-Care Testing (POCT) Market- Industry Trends and Forecast to 2032 is expected to boost market penetration, improve accessibility, and support more comprehensive testing programs, presenting a major opportunity for market expansion.

Restraint/Challenge

  • Limited Awareness and Acceptance

Limited awareness and acceptance of Point-of-Care (POC) Testing can significantly hinder its market growth and widespread adoption. Slow adoption rates among healthcare providers, patients, and payers pose challenges in driving demand and sales for POC devices. Inadequate awareness can lead to limited usage in healthcare settings where these tests are most needed, reducing their impact on patient care and outcomes. Another barrier is the lack of reimbursement, as limited acceptance may result in reduced or denied claims, making it harder for healthcare providers to afford these technologies. Additionally, the absence of proper training and education among healthcare providers can compromise the correct usage and interpretation of POC test results, leading to inaccurate diagnoses.

For instance,

  • In December, 2024, according to the article published in ScienceDirect, the article discusses the challenges and facilitators of adopting point-of-care testing (POCT) for respiratory tract infections (RTIs) in primary care settings, particularly in Australia. Despite advances in technology, POCT adoption remains low due to factors like resource availability, training, quality control, and patient expectations. However, POCT can significantly reduce antimicrobial overuse by providing rapid, evidence-based diagnoses. Facilitating its broader implementation in primary care is crucial for improving antimicrobial stewardship and patient outcomes. The study emphasizes the importance of addressing key barriers and designing strategies to promote the widespread adoption of POCT in managing RTIs
  • In June, 2024, according to the article published in ResearchGate, Point-of-care testing (POCT) offers advantages like speed, convenience, and cost savings but also poses challenges such as lower accuracy, quality control issues, operator dependence, and regulatory concerns. As POCT moves towards decentralized and direct-to-consumer models, careful governance and quality evaluation are necessary to ensure reliable clinical decision-making

To address these challenges, manufacturers should invest in targeted education and training programs for healthcare providers and patients, emphasizing the benefits and correct use of POC testing. Such efforts will help increase awareness, improve adoption, and enhance the overall effectiveness of POC testing in healthcare settings, ultimately driving better patient outcomes.

  • Impact of High Maintenance Costs Threaten Point-Of-Care Testing (POCT) Sustainability in Low-Resource Settings

The high cost of maintenance is a significant challenge in the North America Point-of-Care Testing (POCT) market. Regular calibration, servicing, and maintenance of POCT devices are essential to ensure their continued accuracy, reliability, and performance. However, these activities can incur substantial costs, particularly in low-resource healthcare settings where budgets are constrained. Many POCT devices require periodic technical support, including the replacement of worn-out components, software updates, and ensuring compliance with regulatory standards, all of which contribute to the overall operational expense. For healthcare providers in underfunded areas, allocating resources for such maintenance is often difficult, which can result in prolonged downtimes, increased operational risks, and compromised diagnostic accuracy. In addition, the complexity of some POCT devices means that specialized technicians are required for proper servicing, further driving up maintenance costs. This issue is compounded by the lack of training for local staff to perform basic upkeep tasks, forcing institutions to rely on costly external support. As a result, many healthcare providers may delay or forgo essential maintenance, reducing the overall effectiveness and lifespan of the equipment

For instance,

  • In September, 2020, according to the article published in National Library of Medicine, high costs of point-of-care testing (POCT) present a significant challenge for the North America market. Initial investments in equipment, ongoing maintenance, and training of operators can be prohibitive, especially in low-resource settings. This limits widespread adoption and hinders cost-effectiveness, despite POCT's potential to improve healthcare outcomes
  • In May 2023, according to an article published by National Library of Medicine, the National Center for Biotechnology Information (NCBI) highlights that point-of-care testing (POCT) devices, while beneficial for rapid diagnostics, often face high maintenance costs. Regular calibration and servicing can strain healthcare resources, particularly in low-resource settings, limiting the sustainable use of these technologies

North America Point-Of-Care Testing (POCT) Market Scope

North America point-of-care testing (POCT) market is segmented into six notable segments based on product type, prescription mode, application,  platform, end user, and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product Type

  • Glucose Monitoring Products
    • Strips
    • Meters
    • Lancets And Lancing Devices
  • Infectious Disease Testing Products
    • Covid-19
    • Hiv Testing Products
      • Testing Reagents
      • Testing Equipment
    • Respiratory Infection Testing Products
    • Sexually Transmitted Diseases (Std) Testing
      • Naat-Based Systems
      • Non–Naat-Based Systems
    • Hepatitis C Testing Products
      • Hcv Antibody Tests
      • Hcv Viral Load Tests
    • Influenza Testing Products
      • Traditional Diagnostic Test
        • Rapid Influenza Diagnostic Test (Ridt)
        • Direct Fluorescent Antibody Test (Dfat)
        • Viral Culture
        • Serological Assay
    • Molecular Diagnostic Assay
      • Rt-Pcr
      • Loop-Mediated Isothermal Amplification-Based Assay (Lamp)
      • Nucleic Acid Sequence-Based Amplification Test (Nasbat)
      • Simple Amplification-Based Assay (Samba)
    • Healthcare Associated Infection (Hai) Testing
    • Tropical Disease Testing Products
    • Other Infectious Disease Testing Products
  • Cardiometabolic Monitoring Products
    • Cardiac Marker Testing Products
      • Hstnl
      • Bnp
      • D-Dimer
      • Ck-Mb
      • Myoglobin
  • Blood Gas/Electrolyte Testing Products
    • Blood Gas/Electrolyte Testing Consumables
      • Cartridges
      • Reagents
    • Blood Gas/Electrolyte Testing Instruments
      • Portable
        • Combined Analyzers
        • Blood Gas Analyzers
        • Electrolyte Analyzers
      • Benchtop
        • Combined Analyzers
        • Blood Gas Analyzers
        • Electrolyte Analyzers
  • Hba1c Testing Products
    • Hba1c Testing Instruments
    • Hba1c Testing Consumables
  • Poc Analyzer
  • Ecg Device
    • Resting Ecg Devices
    • Stress Ecg Devices
    • Holter Monitors
  • Pregnancy And Fertility Testing Products
    • Pregnancy Testing Products
      • Strips/ Dip Sticks And Cards
      • Mid Stream Devices
      • Cassettes
      • Digital Devices
      • Line-Indicator Devices
    • Fertility Testing Products
      • Luteinizing Hormone (Lh) Urine Test
      • Fsh Test
      • Others
  • Haematology Testing Products
  • Coagulation Monitoring Products
    • Anticoagulation Monitoring Devices
      • Prothrombin Time/International Normalized Ratio (Pt-Inr) Testing Devices
      • Activated Clotting Time (Act)
      • Activated Partial Thromboplastin Time (Appt)
    • Platelet Function Monitoring Devices
    • Viscoelastic Coagulation Monitoring Devices
      • Rotational Thromboelastometry (Rotem)
      • Thromboelastography (Teg)
  • Drugs-Of-Abuse (Doa) Testing Products
    • Doa Analyzers
      • Immunoassays
      • Chromatographic Devices
      • Breath Analyzers
    • Rapid Testing Devices
      • Urine Testing Devices
      • Oral Fluid Testing Devices
    • Others
  • Urinalysis Testing Products
    • Poc Urine Strip Self-Testing
    • Poc Urine Test Strip Professional Testing
  • Cholesterol Testing Products
    • Testing Kits
    • Instruments
      • Table-Top Analyzers
      • Hand-Held Analyzers
  • Tumor/Cancer Marker Testing Products
  • Fecal Occult Testing Products
    • Guaiac Fob Stool Test
    • Lateral Flow Immuno-Fob Test
    • Immuno-Fob Agglutination Test
    • Immuno-Fob Elisa Test
  • Others

Platform

  • Lateral Flow Assays/Immunochromatography Tests
  • Immunoassays
  • Dipsticks
  • Molecular Diagnostics
  • Clinical Chemistry Assays
  • Microfluidics
  • Hematology
  • Others

Application

  • Blood Glucose
  • Infectious Diseases
    • Covid-19 Testing
    • Hiv Testing
    • Hepatitis C Testing
    • Influenza Testing
    • Tuberculosis Testing
    • Others
  • Vital Sign Monitoring
  • Cardiac Monitoring
  • Coagulation
  • Haematology
  • Non- Invasive Spo2 Monitoring
  • Blood Transfusion
  • Non- Invasive Pco2 Monitoring
  • Whole Blood Analysis
  • Others

Prescription Mode

  • Otc Testing
  • Prescription-Based Testing

End User

  • Hospitals
    • Private
      • Tier 1
      • Tier 2
      • Tier 3
    • Public
      • Tier 1
      • Tier 2
      • Tier 3
  • Home Care
  • Clinics
  • Laboratories
  • Diagnostic Centers
  • Pathology Labs
  • Ambulatory Surgery Centers
  • Elderly Care Centers
  • Others

Distribution Channel

  • Direct Tender
  • Retail Sales
  • Online Sales
  • Others

North America Point-Of-Care Testing (POCT) Market  Regional Analysis

The market is analyzed and market size insights and trends are provided based on country, product type, prescription mode, application,  platform, end user, and distribution channel as referenced above.

The countries covered in the market are U.S., Canada, and Mexico.

U.S. is expected to dominate the Point-of-Care Testing (POCT) market due to its well-established healthcare infrastructure, high adoption rate of advanced diagnostic technologies, rising prevalence of chronic diseases, and strong government support for rapid diagnostics.

U.S. is expected to be the fastest-growing country in the region due to increasing demand for decentralized healthcare, a growing geriatric population, and advancements in molecular POCT technologies.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of North America brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

North America Point-Of-Care Testing (POCT) Market  Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, North America presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

North America Point-Of-Care Testing (POCT) Market  Leaders Operating in the Market Are:

  • F. Hoffmann-La Roche Ltd (Switzerland)
  • Danaher Corporation (U.S.)
  • Siemens Healthineers AG (Germany)
  • BD (Becton, Dickinson and Company) (U.S.)
  • Abbott (U.S.) Pfizer Inc. (U.S.)
  • QuantuMDx Group Ltd. (UK)
  • Thermo Fisher Scientific Inc. (U.S.)
  • Nova Biomedical (U.S.)
  • Trividia Health, Inc. (U.S.)
  • Sienco, Inc. (U.S.)
  • PTS Diagnostics (U.S.)
  • Abaxis (a part of Zoetis) (U.S.)
  • Werfen (Spain)
  • Binx Health (U.S.)
  • BIOMÉRIEUX (France)
  • QIAGEN (Germany)
  • QuidelOrtho Corporation (U.S.)
  • Accubiotech Co., Ltd. (China)
  • Sekisui Diagnostics (U.S.)
  • Trinity Biotech (Ireland)
  • BD Veritor (BD) (U.S.)
  • Hologic, Inc. (U.S.)
  • Sysmex Corporation (Japan)
  • Meridian Bioscience (U.S.)

Latest Developments North America Point-Of-Care Testing (POCT) Market 

  • In December 2023, Roche has acquired select parts of LumiraDx’s innovative Point of Care technology, enhancing its diagnostics portfolio. This acquisition enables faster, more affordable testing across multiple disease areas. The integration of LumiraDx’s platform will improve patient access to timely, accurate diagnostic results in decentralized healthcare settings North Americaly
  • In January 2025, Danaher Corporation has formed an investment partnership with Innovaccer Inc., a healthcare AI company. This collaboration aims to accelerate the adoption of precision diagnostics and value-based care by providing healthcare providers with unified patient data and advanced analytics, improving patient outcomes through personalized, timely interventions
  • In February 2025, BD has announced plans to separate its Biosciences and Diagnostic Solutions businesses to enhance strategic focus, drive growth, and unlock value. The move aims to create two independent entities, each better positioned to capitalize on their respective markets. This decision underscores BD's commitment to strengthening its leadership in healthcare innovation while optimizing operational efficiencies for long-term success
  • In November 2023, Binx Health has partnered with Fisher Healthcare to expand distribution of the FDA-cleared binx io, a molecular point-of-care platform for detecting chlamydia and gonorrhea. This system provides lab-quality results in about 30 minutes, improving timely diagnoses and enabling clinicians to test and treat patients during a single visit, enhancing care access
  • In April 2023,  Binx Health is expanding its commercial organization to meet the growing demand for its FDA-cleared, CLIA-waived binx io platform, which detects chlamydia and gonorrhea in 30 minutes. This molecular point-of-care solution offers central lab-equivalent performance and addresses the urgent need for accessible, timely STI testing, improving care across the U.S.

SKU-

Get online access to the report on the World's First Market Intelligence Cloud

Sample Image Click on image to enlarge
  • Interactive Data Analysis Dashboard
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
  • Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Request for Demo

Table of Content

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF THE NORTH AMERICA POINT-OF-CARE-TESTING (POCT) MARKET

1.4 CURRENCY AND PRICING

1.5 LIMITATIONS

1.6 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 DBMR TRIPOD DATA VALIDATION MODEL

2.5 MULTIVARIATE MODELLING

2.6 TYPE LIFELINE CURVE

2.7 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.8 DBMR MARKET POSITION GRID

2.9 MARKET END USER COVERAGE GRID

2.1 VENDOR SHARE ANALYSIS

2.11 SECONDARY SOURCES

2.12 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PORTER’S FIVE FORCES

4.2 PESTEL ANALYSIS

4.3 HEALTHCARE ECONOMY

4.3.1 HEALTHCARE EXPENDITURE

4.3.2 CAPEX TRENDS

4.3.3 CAPEX ALLOCATION

4.3.4 FUNDING SOURCES

4.3.5 INDUSTRY BENCHMARKS

4.3.6 GDP RATIO IN OVERALL GDP

4.3.7 HEALTHCARE SYSTEM STRUCTURE

4.3.8 GOVERNMENT POLICIES

4.3.9 ECONOMIC DEVELOPMENT

4.4 MICRO AND MACRO ECONOMIC FACTORS

4.5 TECHNOLOGY ROADMAP: NORTH AMERICA POINT OF CARE TESTING

5 NORTH AMERICA POINT-OF-CARE TESTING (POCT) MARKET: REGULATIONS

6 MARKET OVERVIEW

6.1 DRIVERS

6.1.1 RISING USE OF POC TESTING IN HEALTHCARE FACILITIES

6.1.2 RISING INCIDENCE OF SUBSTANCE ABUSE

6.1.3 INCREASED ADOPTION OF TELEMEDICINE

6.1.4 ADVANCEMENTS TECHNOLOGIES ENHANCING POC TESTING WITH BIOSENSORS AND MOBILE INTEGRATION

6.2 RESTRAINTS

6.2.1 DATA SECURITY AND PRIVACY CONCERNS

6.2.2 LACK OF ACCURACY AND TECHNICAL CHALLENGES

6.3 OPPORTUNITIES

6.3.1 RISING AWARENESS AND ADVOCACY FOR POINT-OF-CARE TESTING

6.3.2 STRATEGIC INITIATION AND DECISION TAKEN BY THE MARKET PLAYERS

6.3.3 EXPANDING PRODUCT RANGE FOR POINT-OF-CARE TESTING

6.4 CHALLENGES

6.4.1 LIMITED AWARENESS AND ACCEPTANCE

6.4.2 IMPACT OF HIGH MAINTENANCE COSTS THREATEN POINT-OF-CARE TESTING (POCT) SUSTAINABILITY IN LOW-RESOURCE SETTINGS

7 NORTH AMERICA POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT TYPE

7.1 OVERVIEW

7.2 GLUCOSE MONITORING PRODUCTS

7.2.1 STRIPS

7.2.2 METERS

7.2.3 LANCETS AND LANCING DEVICES

7.3 INFECTIOUS DISEASE TESTING PRODUCTS

7.3.1 COVID-19

7.3.2 HIV TESTING PRODUCTS

7.3.2.1 TESTING REAGENTS

7.3.2.2 TESTING EQUIPMENT

7.3.3 RESPIRATORY INFECTION TESTING PRODUCTS

7.3.4 SEXUALLY TRANSMITTED DISEASES (STD) TESTING

7.3.4.1 NAAT-BASED SYSTEMS

7.3.4.2 NON–NAAT-BASED SYSTEMS

7.3.5 HEPATITIS C TESTING PRODUCTS

7.3.5.1 HCV ANTIBODY TESTS

7.3.5.2 HCV VIRAL LOAD TESTS

7.3.6 INFLUENZA TESTING PRODUCTS

7.3.6.1 TRADITIONAL DIAGNOSTIC TEST

7.3.6.1.1 RAPID INFLUENZA DIAGNOSTIC TEST (RIDT)

7.3.6.1.2 DIRECT FLUORESCENT ANTIBODY TEST (DFAT)

7.3.6.1.3 VIRAL CULTURE

7.3.6.1.4 SEROLOGICAL ASSAY

7.3.6.2 MOLECULAR DIAGNOSTIC ASSAY

7.3.6.2.1 RT-PCR

7.3.6.2.2 LOOP-MEDIATED ISOTHERMAL AMPLIFICATION-BASED ASSAY (LAMP)

7.3.6.2.3 NUCLEIC ACID SEQUENCE-BASED AMPLIFICATION TEST (NASBAT)

7.3.6.2.4 SIMPLE AMPLIFICATION-BASED ASSAY (SAMBA)

7.3.7 HEALTHCARE ASSOCIATED INFECTION (HAI) TESTING

7.3.8 TROPICAL DISEASE TESTING PRODUCTS

7.3.9 OTHER INFECTIOUS DISEASE TESTING PRODUCTS

7.4 CARDIOMETABOLIC MONITORING PRODUCTS

7.4.1 CARDIAC MARKER TESTING PRODUCTS

7.4.1.1 HSTNL

7.4.1.2 BNP

7.4.1.3 D-DIMER

7.4.1.4 CK-MB

7.4.1.5 MYOGLOBIN

7.4.2 BLOOD GAS/ELECTROLYTE TESTING PRODUCTS

7.4.2.1 BLOOD GAS/ELECTROLYTE TESTING CONSUMABLES

7.4.2.1.1 CARTRIDGES

7.4.2.1.2 REAGENTS

7.4.2.2 BLOOD GAS/ELECTROLYTE TESTING INSTRUMENTS

7.4.2.2.1 PORTABLE

7.4.2.2.1.1 COMBINED ANALYZERS

7.4.2.2.1.2 BLOOD GAS ANALYZERS

7.4.2.2.1.3 ELECTROLYTE ANALYZERS

7.4.2.2.2 BENCHTOP

7.4.2.2.2.1 Combined Analyzers

7.4.2.2.2.2 Blood Gas Analyzers

7.4.2.2.2.3 Electrolyte Analyzers

7.4.3 HBA1C TESTING PRODUCTS

7.4.3.1 HBA1C TESTING INSTRUMENTS

7.4.3.2 HBA1C TESTING CONSUMABLES

7.4.4 POC ANALYZER

7.4.5 ECG DEVICE

7.4.5.1 RESTING ECG DEVICES

7.4.5.2 STRESS ECG DEVICES

7.4.5.3 HOLTER MONITORS

7.5 PREGNANCY AND FERTILITY TESTING PRODUCTS

7.6 PREGNANCY TESTING PRODUCTS AND FERTILITY TESTING PRODUCTS

7.6.1 STRIPS/ DIP STICKS AND CARDS

7.6.2 MID STREAM DEVICES

7.6.3 CASSETTES

7.6.4 DIGITAL DEVICES

7.6.5 LINE-INDICATOR DEVICES

7.6.6 LUTEINIZING HORMONE (LH) URINE TEST

7.6.7 FSH TEST

7.6.8 OTHERS

7.7 HAEMATOLOGY TESTING PRODUCTS

7.8 COAGULATION MONITORING PRODUCTS

7.8.1 ANTICOAGULATION MONITORING DEVICES

7.8.1.1 PROTHROMBIN TIME/INTERNATIONAL NORMALIZED RATIO (PT-INR) TESTING DEVICES

7.8.1.2 ACTIVATED CLOTTING TIME (ACT)

7.8.1.3 ACTIVATED PARTIAL THROMBOPLASTIN TIME (APPT)

7.8.2 PLATELET FUNCTION MONITORING DEVICES

7.8.3 VISCOELASTIC COAGULATION MONITORING DEVICES

7.8.3.1 ROTATIONAL THROMBOELASTOMETRY (ROTEM)

7.8.3.2 THROMBOELASTOGRAPHY (TEG)

7.9 DRUG-OF-ABUSE (DOA) TESTING PRODUCTS

7.9.1 DOA ANALYSERS

7.9.1.1 IMMUNOASSAYS

7.9.1.2 CHROMATOGRAPHIC DEVICES

7.9.1.3 BREATH ANALYSERS

7.9.2 RAPID TESTING DEVICES

7.9.2.1 URINE TESTING DEVICES

7.9.2.2 ORAL FLUID TESTING DEVICES

7.9.3 OTHERS

7.1 URINALYSIS TESTING PRODUCTS

7.10.1 POC URINE STRIP SELF-TESTING

7.10.2 POC URINE TEST STRIP PROFESSIONAL TESTING

7.11 CHOLESTEROL TESTING PRODUCTS

7.11.1 TESTING KITS

7.11.2 INSTRUMENTS

7.11.2.1 TABLE-TOP ANALYZERS

7.11.2.2 HAND-HELD ANALYZERS

7.12 TUMOR/CANCER MARKER TESTING PRODUCTS

7.13 FECAL OCCULT TESTING PRODUCTS

7.13.1 GUAIAC FOB STOOL TEST

7.13.2 LATERAL FLOW IMMUNO-FOB TEST

7.13.3 IMMUNO-FOB AGGLUTINATION TEST

7.13.4 IMMUNO-FOB ELISA TEST

7.14 OTHERS

8 NORTH AMERICA POINT-OF-CARE TESTING (POCT) MARKET, BY PRESCRIPTION MODE

8.1 OVERVIEW

8.2 OTC TESTING

8.3 PRESCRIPTION-BASED TESTING

9 NORTH AMERICA POINT-OF-CARE TESTING (POCT) MARKET, BY PLATFORM

9.1 OVERVIEW

9.2 LATERAL FLOW ASSAYS/IMMUNOCHROMATOGRAPHY TESTS

9.3 IMMUNOASSAYS

9.4 DIPSTICKS

9.5 MOLECULAR DIAGNOSTICS

9.6 CLINICAL CHEMISTRY ASSAYS

9.7 MICROFLUIDICS

9.8 HEMATOLOGY

9.9 OTHERS

10 NORTH AMERICA POINT-OF-CARE-TESTING (POCT) MARKET, BY APPLICATION

10.1 OVERVIEW

10.2 BLOOD GLUCOSE

10.3 INFECTIOUS DISEASES

10.3.1 COVID-19 TESTING

10.3.2 HIV TESTING

10.3.3 HEPATITIS C TESTING

10.3.4 INFLUENZA TESTING

10.3.5 TUBERCULOSIS TESTING

10.3.6 OTHERS

10.4 VITAL SIGN MONITORING

10.5 CARDIAC MONITORING

10.6 COAGULATION

10.7 HAEMATOLOGY

10.8 NON- INVASIVE SPO2 MONITORING

10.9 BLOOD TRANSFUSION

10.1 NON- INVASIVE PCO2 MONITORING

10.11 WHOLE BLOOD ANALYSIS

10.12 OTHERS

11 NORTH AMERICA POINT-OF-CARE TESTING (POCT) MARKET, BY END USER

11.1 OVERVIEW

11.2 HOSPITALS

11.2.1 PRIVATE

11.2.2 PUBLIC

11.2.3 PRIVATE IF FURTHER SUB-SEGMENTED INTO TIER 1, TIER 2 AND TIER 3.

11.2.3.1 Tier 1

11.2.3.2 Tier 2

11.2.3.3 Tier 3

11.3 HOME CARE

11.4 CLINICS

11.5 LABORATORIES

11.6 DIAGNOSTIC CENTERS

11.7 PATHOLOGY LABS

11.8 AMBULATORY SURGERY CENTERS

11.9 ELDERLY CARE CENTERS

11.1 OTHERS

12 NORTH AMERICA POINT-OF-CARE-TESTING (POCT) MARKET, BY DISTRIBUTION CHANNEL

12.1 OVERVIEW

12.2 DIRECT TENDER

12.3 RETAIL SALES

12.4 ONLINE SALES

12.5 OTHERS

13 NORTH AMERICA POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION

13.1 NORTH AMERICA

13.1.1 U.S

13.1.2 CANADA

13.1.3 MEXICO

14 NORTH AMERICA POINT-OF-CARE TESTING (POCT) MARKET: COMPANY LANDSCAPE

14.1 COMPANY SHARE ANALYSIS: GLOBAL

15 SWOT ANALYSIS

16 COMPANY PROFILES

16.1 F. HOFFMANN-LA ROCHE LTD

16.1.1 COMPANY SNAPSHOT

16.1.2 REVENUE ANALYSIS

16.1.3 COMPANY SHARE ANALYSIS

16.1.4 PRODUCT PORTFOLIO

16.1.5 RECENT DEVELOPMENT

16.2 DANAHER

16.2.1 COMPANY SNAPSHOT

16.2.2 REVENUE ANALYSIS

16.2.3 COMPANY SHARE ANALYSIS

16.2.4 PRODUCT PORTFOLIO

16.2.5 RECENT DEVELOPMENT

16.3 SIEMENS HEALTHINEERS AG

16.3.1 COMPANY SNAPSHOT

16.3.2 REVENUE ANALYSIS

16.3.3 COMPANY SHARE ANALYSIS

16.3.4 PRODUCT PORTFOLIO

16.3.5 RECENT DEVELOPMENT

16.4 BD VERITOR(BD)

16.4.1 COMPANY SNAPSHOT

16.4.2 REVENUE ANALYSIS

16.4.3 COMPANY SHARE ANALYSIS

16.4.4 PRODUCT PORTFOLIO

16.4.5 RECENT DEVELOPMENT

16.5 ABBOTT POINT OF CARE INC(ABBOTT)

16.5.1 COMPANY SNAPSHOT

16.5.2 REVENUE ANALYSIS

16.5.3 COMPANY SHARE ANALYSIS

16.5.4 PRODUCT PORTFOLIO

16.5.5 RECENT DEVELOPMENT

16.6 ACCUBIOTECH CO., LTD.

16.6.1 COMPANY SNAPSHOT

16.6.2 PRODUCT PORTFOLIO

16.6.3 RECENT DEVELOPMENT

16.7 ABAXIS (ABAXIS IS A PART OF ZOETIS)

16.7.1 COMPANY SNAPSHOT

16.7.2 PRODUCT PORTFOLIO

16.7.3 RECENT DEVELOPMENT

16.8 BINX HEALTH

16.8.1 COMPANY SNAPSHOT

16.8.2 SOLUTION PORTFOLIO

16.8.3 RECENT DEVELOPMENT

16.9 BIOMERIEUX

16.9.1 COMPANY SNAPSHOT

16.9.2 REVENUE ANALYSIS

16.9.3 PRODUCT PORTFOLIO

16.9.4 RECENT DEVELOPMENT

16.1 BIO- RAD LABORATORIES, INC.

16.10.1 COMPANY SNAPSHOT

16.10.2 PRODUCT PORTFOLIO

16.10.3 RECENT DEVELOPMENT

16.11 CHEMBIO DIAGNOSTICS, INC.

16.11.1 COMPANY SNAPSHOT

16.11.2 PRODUCT PORTFOLIO

16.11.3 RECENT DEVELOPMENT

16.12 EKF DIAGNOSTICS HOLDINGS PLC

16.12.1 COMPANY SNAPSHOT

16.12.2 PRODUCT PORTFOLIO

16.12.3 RECENT DEVELOPMENT

16.13 HOLOGIC, INC

16.13.1 COMPANY SNAPSHOT

16.13.2 REVENUE ANALYSIS

16.13.3 PRODUCT PORTFOLIO

16.13.4 RECENT DEVELOPMENT

16.14 LAMDAGEN CORPORATION

16.14.1 COMPANY SNAPSHOT

16.14.2 PRODUCT PORTFOLIO

16.14.3 RECENT DEVELOPMENT

16.15 MERIDIAN BIOSCIENCE

16.15.1 COMPANY SNAPSHOT

16.15.2 PRODUCT PORTFOLIO

16.15.3 RECENT DEVELOPMENT

16.16 NOVA BIOMEDICAL

16.16.1 COMPANY SNAPSHOT

16.16.2 PRODUCT PORTFOLIO

16.16.3 RECENT DEVELOPMENT

16.17 PFIZER INC.

16.17.1 COMPANY SNAPSHOT

16.17.2 PRODUCT PORTFOLIO

16.17.3 RECENT DEVELOPMENT

16.18 PTS DIAGNOSTICS

16.18.1 COMPANY SNAPSHOT

16.18.2 PRODUCT PORTFOLIO

16.18.3 RECENT DEVELOPMENT

16.19 QIAGEN

16.19.1 COMPANY SNAPSHOT

16.19.2 REVENUE ANALYSIS

16.19.3 PRODUCT PORTFOLIO

16.19.4 RECENT DEVELOPMENT

16.2 QUIDELORTHO CORPORATION

16.20.1 COMPANY SNAPSHOT

16.20.2 REVENUE ANALYSIS

16.20.3 PRODUCT PORTFOLIO

16.20.4 RECENT DEVELOPMENT

16.21 QUANTUMDX GROUP LTD.

16.21.1 COMPANY SNAPSHOT

16.21.2 PRODUCT PORTFOLIO

16.21.3 RECENT DEVELOPMENT

16.22 SEKISUI DIAGNOSTICS

16.22.1 COMPANY SNAPSHOT

16.22.2 PRODUCT PORTFOLIO

16.22.3 RECENT. DEVELOPMENT

16.23 SIENCO, INC.

16.23.1 COMPANY SNAPSHOT

16.23.2 PRODUCT PORTFOLIO

16.23.3 RECENT UPDATES

16.24 SYSMEX CORPORATION

16.24.1 COMPANY SNAPSHOT

16.24.2 REVENUE ANALYSIS

16.24.3 PRODUCT PORTFOLIO

16.24.4 RECENT DEVELOPMENT

16.25 TRINITY BIOTECH

16.25.1 COMPANY SNAPSHOT

16.25.2 REVENUE ANALYSIS

16.25.3 PRODUCT PORTFOLIO

16.25.4 RECENT DEVELOPMENT

16.26 TRIVIDIA HEALTH, INC.

16.26.1 COMPANY SNAPSHOT

16.26.2 PRODUCT PORTFOLIO

16.26.3 RECENT UPDATES

16.27 THERMO FISHER SCIENTIFIC INC.

16.27.1 COMPANY SNAPSHOT

16.27.2 REVENUE ANALYSIS

16.27.3 PRODUCT PORTFOLIO

16.27.4 RECENT DEVELOPMENT

16.28 WERFEN

16.28.1 COMPANY SNAPSHOT

16.28.2 PRODUCT PORTFOLIO

16.28.3 RECENT DEVELOPMENT

17 QUESTIONNAIRE

18 RELATED REPORTS

List of Table

TABLE 1 NORTH AMERICA POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 2 NORTH AMERICA POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 3 NORTH AMERICA POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 4 NORTH AMERICA GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 5 NORTH AMERICA GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 6 NORTH AMERICA GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 7 NORTH AMERICA GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 8 NORTH AMERICA INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 9 NORTH AMERICA INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSANDS)

TABLE 10 NORTH AMERICA HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 11 NORTH AMERICA HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 12 NORTH AMERICA HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 13 NORTH AMERICA SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 14 NORTH AMERICA SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 15 NORTH AMERICA SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 16 NORTH AMERICA HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSANDS)

TABLE 17 NORTH AMERICA HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 18 NORTH AMERICA HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 19 NORTH AMERICA INFLUENZA TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 20 NORTH AMERICA TRADITIONAL DIAGNOSTIC TEST IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 21 NORTH AMERICA TRADITIONAL DIAGNOSTIC TEST IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 22 NORTH AMERICA TRADITIONAL DIAGNOSTIC TEST IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 23 NORTH AMERICA MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 24 NORTH AMERICA MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 25 NORTH AMERICA MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 26 NORTH AMERICA INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (VOLUME IN THOUSANDS UNITS)

TABLE 27 NORTH AMERICA INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 28 NORTH AMERICA CARDIOMETABOLIC MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 29 NORTH AMERICA CARDIOMETABOLIC MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 30 NORTH AMERICA CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 31 NORTH AMERICA CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 32 NORTH AMERICA CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 33 NORTH AMERICA BLOOD GAS/ELECTROLYTE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 34 NORTH AMERICA BLOOD GAS/ELECTROLYTE TESTING CONSUMABLES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 35 NORTH AMERICA BLOOD GAS/ELECTROLYTE TESTING CONSUMABLES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 36 NORTH AMERICA BLOOD GAS/ELECTROLYTE TESTING CONSUMABLES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 37 NORTH AMERICA BLOOD GAS/ELECTROLYTE TESTING INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 38 NORTH AMERICA PORTABLE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 39 NORTH AMERICA PORTABLE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 40 NORTH AMERICA PORTABLE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 41 NORTH AMERICA BENCHTOP IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSANDS)

TABLE 42 NORTH AMERICA BENCHTOP IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 43 NORTH AMERICA BENCHTOP IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 44 NORTH AMERICA HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 45 NORTH AMERICA HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 46 NORTH AMERICA HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 47 NORTH AMERICA POC ANALYZER IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 48 NORTH AMERICA POC ANALYZER IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 49 NORTH AMERICA ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 50 NORTH AMERICA ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 51 NORTH AMERICA ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 52 NORTH AMERICA PREGNANCY AND FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 53 NORTH AMERICA PREGNANCY AND FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 54 NORTH AMERICA PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 55 NORTH AMERICA PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (VOLUME IN THOUSANDS UNITS)

TABLE 56 NORTH AMERICA PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 57 NORTH AMERICA FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 58 NORTH AMERICA FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 59 NORTH AMERICA FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 60 NORTH AMERICA HAEMATOLOGY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 61 NORTH AMERICA COAGULATION MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 62 NORTH AMERICA COAGULATION MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSANDS)

TABLE 63 NORTH AMERICA ANTICOAGULATION MONITORING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 64 NORTH AMERICA ANTICOAGULATION MONITORING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 65 NORTH AMERICA ANTICOAGULATION MONITORING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 66 NORTH AMERICA VISCOELASTIC COAGULATION MONITORING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY METHOD, 2018-2032 (USD THOUSANDS)

TABLE 67 NORTH AMERICA DRUGS-OF-ABUSE (DOA) TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 68 NORTH AMERICA DRUG-OF-ABUSE (DOA) TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 69 NORTH AMERICA DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSANDS)

TABLE 70 NORTH AMERICA DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (VOLUME IN THOUSAND UNIT)

TABLE 71 NORTH AMERICA DOA ANALYZERS MONITORING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 72 NORTH AMERICA RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 73 NORTH AMERICA RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 74 NORTH AMERICA RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 75 NORTH AMERICA URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 76 NORTH AMERICA URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 77 NORTH AMERICA URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 78 NORTH AMERICA URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 79 NORTH AMERICA CHOLESTEROL TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 80 NORTH AMERICA CHOLESTEROL TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 81 NORTH AMERICA CHOLESTEROL TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (VOLUME IN THOUSANDS UNITS)

TABLE 82 NORTH AMERICA CHOLESTEROL TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 83 NORTH AMERICA INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSANDS)

TABLE 84 NORTH AMERICA INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 85 NORTH AMERICA INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 86 NORTH AMERICA TUMOR/CANCER MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 87 NORTH AMERICA FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 88 NORTH AMERICA FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 89 NORTH AMERICA FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (VOLUME IN THOUSANDS UNITS)

TABLE 90 NORTH AMERICA FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 91 NORTH AMERICA OTHERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 92 NORTH AMERICA POINT-OF-CARE-TESTING (POCT) MARKET, BY PRESCRIPTION MODE, 2018-2032 (USD THOUSANDS)

TABLE 93 NORTH AMERICA OTC TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 94 NORTH AMERICA PRESCRIPTION-BASED TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2032 (USD THOUSANDS)

TABLE 95 NORTH AMERICA POINT-OF-CARE-TESTING (POCT) MARKET, BY PLATFORM, 2018-2032 (USD THOUSAND)

TABLE 96 NORTH AMERICA LATERAL FLOW ASSAYS/IMMUNOCHROMATOGRAPHY TESTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2032 (USD THOUSANDS)

TABLE 97 NORTH AMERICA IMMUNOASSAYS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2032 (USD THOUSANDS)

TABLE 98 NORTH AMERICA DIPSTICKS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2032 (USD THOUSANDS)

TABLE 99 NORTH AMERICA MOLECULAR DIAGNOSTICS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2032 (USD THOUSANDS)

TABLE 100 NORTH AMERICA CLINICAL CHEMISTRY ASSAYS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 101 NORTH AMERICA MICROFLUIDICS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2032 (USD THOUSANDS)

TABLE 102 NORTH AMERICA HEMATOLOGY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2032 (USD THOUSANDS)

TABLE 103 NORTH AMERICA OTHERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2032 (USD THOUSANDS)

TABLE 104 NORTH AMERICA POINT-OF-CARE-TESTING (POCT) MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 105 NORTH AMERICA BLOOD GLUCOSE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 106 NORTH AMERICA INFECTIOUS DISEASES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 107 NORTH AMERICA INFECTIOUS DISEASES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 108 NORTH AMERICA VITAL SIGN MONITORING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 109 NORTH AMERICA CARDIAC MONITORING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 110 NORTH AMERICA COAGULATION IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 111 NORTH AMERICA HAEMATOLOGY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 112 NORTH AMERICA NON- INVASIVE SPO2 MONITORING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 113 NORTH AMERICA BLOOD TRANSFUSION IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 114 NORTH AMERICA NON- INVASIVE PCO2 MONITORING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 115 NORTH AMERICA WHOLE BLOOD ANALYSIS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 116 NORTH AMERICA OTHERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 117 NORTH AMERICA POINT-OF-CARE-TESTING (POCT) MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 118 NORTH AMERICA HOSPITALS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2032 (USD THOUSANDS)

TABLE 119 NORTH AMERICA HOSPITALS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY TYPE, 2018-2032 (USD THOUSANDS)

TABLE 120 NORTH AMERICA PRIVATE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY LEVEL, 2018-2032 (USD THOUSANDS)

TABLE 121 NORTH AMERICA PUBLIC IN POINT-OF-CARE-TESTING (POCT) MARKET, BY LEVEL, 2018-2032 (USD THOUSANDS)

TABLE 122 NORTH AMERICA HOME CARE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 123 NORTH AMERICA CLINICS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 124 NORTH AMERICA LABORATORIES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 125 NORTH AMERICA DIAGNOSTIC CENTERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 126 NORTH AMERICA PATHOLOGY LABS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 127 NORTH AMERICA AMBULATORY SURGERY CENTERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 128 NORTH AMERICA ELDERLY CARE CENTERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 129 NORTH AMERICA OTHERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 130 NORTH AMERICA POINT-OF-CARE-TESTING (POCT) MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 131 NORTH AMERICA DIRECT TENDER IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2032 (USD MILLIONS)

TABLE 132 NORTH AMERICA RETAIL SALES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2032 (USD MILLIONS)

TABLE 133 NORTH AMERICA ONLINE SALES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2032 (USD MILLIONS)

TABLE 134 NORTH AMERICA OTHERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2032 (USD MILLIONS)

TABLE 135 NORTH AMERICA POINT-OF-CARE-TESTING (POCT) MARKET, BY COUNTRY, 2018-2032 (USD THOUSAND)

TABLE 136 NORTH AMERICA POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 137 NORTH AMERICA POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 138 NORTH AMERICA POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 139 NORTH AMERICA GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 140 NORTH AMERICA GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 141 NORTH AMERICA GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 142 NORTH AMERICA INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 143 NORTH AMERICA INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 144 NORTH AMERICA INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 145 NORTH AMERICA HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 146 NORTH AMERICA HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 147 NORTH AMERICA SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 148 NORTH AMERICA SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 149 NORTH AMERICA SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 150 NORTH AMERICA HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 151 NORTH AMERICA HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 152 NORTH AMERICA HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 153 NORTH AMERICA INFLUENZA TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 154 NORTH AMERICA TRADITIONAL DIAGNOSTIC TEST IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 155 NORTH AMERICA TRADITIONAL DIAGNOSTIC TEST IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 156 NORTH AMERICA TRADITIONAL DIAGNOSTIC TEST IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 157 NORTH AMERICA MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 158 NORTH AMERICA MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 159 NORTH AMERICA MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 160 NORTH AMERICA CARDIOMETABOLIC MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 161 NORTH AMERICA POC ANALYZER IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 162 NORTH AMERICA POC ANALYZER IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 163 NORTH AMERICA CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 164 NORTH AMERICA CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 165 NORTH AMERICA CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 166 NORTH AMERICA BLOOD GAS/ELECTROLYTE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 167 NORTH AMERICA BLOOD GAS/ELECTROLYTE TESTING CONSUMABLES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 168 NORTH AMERICA BLOOD GAS/ELECTROLYTE TESTING CONSUMABLES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 169 NORTH AMERICA BLOOD GAS/ELECTROLYTE TESTING CONSUMABLES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 170 NORTH AMERICA BLOOD GAS/ELECTROLYTE TESTING INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 171 NORTH AMERICA PORTABLE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 172 NORTH AMERICA PORTABLE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 173 NORTH AMERICA PORTABLE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 174 NORTH AMERICA BENCHTOP IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 175 NORTH AMERICA BENCHTOP IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 176 NORTH AMERICA BENCHTOP IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 177 NORTH AMERICA HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 178 NORTH AMERICA HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 179 NORTH AMERICA HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 180 NORTH AMERICA ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 181 NORTH AMERICA ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 182 NORTH AMERICA ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 183 NORTH AMERICA PREGNANCY AND FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 184 NORTH AMERICA PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 185 NORTH AMERICA PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 186 NORTH AMERICA PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 187 NORTH AMERICA FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 188 NORTH AMERICA FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 189 NORTH AMERICA FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 190 NORTH AMERICA COAGULATION MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 191 NORTH AMERICA ANTICOAGULATION MONITORING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 192 NORTH AMERICA ANTICOAGULATION MONITORING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 193 NORTH AMERICA ANTICOAGULATION MONITORING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 194 NORTH AMERICA VISCOELASTIC COAGULATION MONITORING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY METHOD, 2018-2032 (USD THOUSAND)

TABLE 195 NORTH AMERICA DRUG-OF-ABUSE (DOA) TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 196 NORTH AMERICA DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 197 NORTH AMERICA DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 198 NORTH AMERICA DOA ANALYZERS MONITORING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 199 NORTH AMERICA RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 200 NORTH AMERICA RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 201 NORTH AMERICA RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 202 NORTH AMERICA URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 203 NORTH AMERICA URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 204 NORTH AMERICA URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 205 NORTH AMERICA CHOLESTEROL TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 206 NORTH AMERICA CHOLESTEROL TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 207 NORTH AMERICA CHOLESTEROL TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 208 NORTH AMERICA INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 209 NORTH AMERICA INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 210 NORTH AMERICA INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 211 NORTH AMERICA FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 212 NORTH AMERICA FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 213 NORTH AMERICA FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 214 NORTH AMERICA POINT-OF-CARE-TESTING (POCT) MARKET, BY PLATFORM, 2018-2032 (USD THOUSAND)

TABLE 215 NORTH AMERICA POINT-OF-CARE-TESTING (POCT) MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 216 NORTH AMERICA INFECTIOUS DISEASES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 217 NORTH AMERICA POINT-OF-CARE-TESTING (POCT) MARKET, BY PRESCRIPTION MODE, 2018-2032 (USD THOUSAND)

TABLE 218 NORTH AMERICA POINT-OF-CARE-TESTING (POCT) MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 219 NORTH AMERICA HOSPITALS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 220 NORTH AMERICA PRIVATE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY LEVEL, 2018-2032 (USD THOUSAND)

TABLE 221 NORTH AMERICA PUBLIC IN POINT-OF-CARE-TESTING (POCT) MARKET, BY LEVEL, 2018-2032 (USD THOUSAND)

TABLE 222 NORTH AMERICA POINT-OF-CARE-TESTING (POCT) MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 223 U.S. POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 224 U.S. POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 225 U.S. POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 226 U.S. GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 227 U.S. GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 228 U.S. GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 229 U.S. INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 230 U.S. INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 231 U.S. INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 232 U.S. HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 233 U.S. HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 234 U.S. HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 235 U.S. SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 236 U.S. SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 237 U.S. SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 238 U.S. HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 239 U.S. HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 240 U.S. HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 241 U.S. INFLUENZA TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 242 U.S. TRADITIONAL DIAGNOSTIC TEST IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 243 U.S. TRADITIONAL DIAGNOSTIC TEST IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 244 U.S. TRADITIONAL DIAGNOSTIC TEST IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 245 U.S. MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 246 U.S. MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 247 U.S. MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 248 U.S. CARDIOMETABOLIC MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 249 U.S. POC ANALYZER IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 250 U.S. POC ANALYZER IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 251 U.S. CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 252 U.S. CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 253 U.S. CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 254 U.S. BLOOD GAS/ELECTROLYTE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 255 U.S. BLOOD GAS/ELECTROLYTE TESTING CONSUMABLES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 256 U.S. BLOOD GAS/ELECTROLYTE TESTING CONSUMABLES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 257 U.S. BLOOD GAS/ELECTROLYTE TESTING CONSUMABLES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 258 U.S. BLOOD GAS/ELECTROLYTE TESTING INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 259 U.S. PORTABLE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 260 U.S. PORTABLE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 261 U.S. PORTABLE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 262 U.S. BENCHTOP IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 263 U.S. BENCHTOP IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 264 U.S. BENCHTOP IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 265 U.S. HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 266 U.S. HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 267 U.S. HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 268 U.S. ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 269 U.S. ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 270 U.S. ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 271 U.S. PREGNANCY AND FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 272 U.S. PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 273 U.S. PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 274 U.S. PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 275 U.S. FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 276 U.S. FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 277 U.S. FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 278 U.S. COAGULATION MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 279 U.S. ANTICOAGULATION MONITORING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 280 U.S. ANTICOAGULATION MONITORING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 281 U.S. ANTICOAGULATION MONITORING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 282 U.S. VISCOELASTIC COAGULATION MONITORING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY METHOD, 2018-2032 (USD THOUSAND)

TABLE 283 U.S. DRUG-OF-ABUSE (DOA) TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 284 U.S. DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 285 U.S. DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 286 U.S. DOA ANALYZERS MONITORING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 287 U.S. RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 288 U.S. RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 289 U.S. RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 290 U.S. URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 291 U.S. URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 292 U.S. URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 293 U.S. CHOLESTEROL TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 294 U.S. CHOLESTEROL TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 295 U.S. CHOLESTEROL TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 296 U.S. INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 297 U.S. INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 298 U.S. INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 299 U.S. FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 300 U.S. FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 301 U.S. FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 302 U.S. POINT-OF-CARE-TESTING (POCT) MARKET, BY PLATFORM, 2018-2032 (USD THOUSAND)

TABLE 303 U.S. POINT-OF-CARE-TESTING (POCT) MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 304 U.S. INFECTIOUS DISEASES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 305 U.S. POINT-OF-CARE-TESTING (POCT) MARKET, BY PRESCRIPTION MODE, 2018-2032 (USD THOUSAND)

TABLE 306 U.S. POINT-OF-CARE-TESTING (POCT) MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 307 U.S. HOSPITALS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 308 U.S. PRIVATE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY LEVEL, 2018-2032 (USD THOUSAND)

TABLE 309 U.S. PUBLIC IN POINT-OF-CARE-TESTING (POCT) MARKET, BY LEVEL, 2018-2032 (USD THOUSAND)

TABLE 310 U.S. POINT-OF-CARE-TESTING (POCT) MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 311 CANADA POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 312 CANADA POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 313 CANADA POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 314 CANADA GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 315 CANADA GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 316 CANADA GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 317 CANADA INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 318 CANADA INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 319 CANADA INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 320 CANADA HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 321 CANADA HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 322 CANADA HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 323 CANADA SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 324 CANADA SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 325 CANADA SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 326 CANADA HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 327 CANADA HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 328 CANADA HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 329 CANADA INFLUENZA TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 330 CANADA TRADITIONAL DIAGNOSTIC TEST IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 331 CANADA TRADITIONAL DIAGNOSTIC TEST IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 332 CANADA TRADITIONAL DIAGNOSTIC TEST IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 333 CANADA MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 334 CANADA MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 335 CANADA MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 336 CANADA CARDIOMETABOLIC MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 337 CANADA POC ANALYZER IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 338 CANADA POC ANALYZER IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 339 CANADA CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 340 CANADA CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 341 CANADA CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 342 CANADA BLOOD GAS/ELECTROLYTE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 343 CANADA BLOOD GAS/ELECTROLYTE TESTING CONSUMABLES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 344 CANADA BLOOD GAS/ELECTROLYTE TESTING CONSUMABLES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 345 CANADA BLOOD GAS/ELECTROLYTE TESTING CONSUMABLES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 346 CANADA BLOOD GAS/ELECTROLYTE TESTING INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 347 CANADA PORTABLE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 348 CANADA PORTABLE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 349 CANADA PORTABLE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 350 CANADA BENCHTOP IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 351 CANADA BENCHTOP IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 352 CANADA BENCHTOP IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 353 CANADA HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 354 CANADA HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 355 CANADA HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 356 CANADA ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 357 CANADA ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 358 CANADA ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 359 CANADA PREGNANCY AND FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 360 CANADA PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 361 CANADA PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 362 CANADA PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 363 CANADA FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 364 CANADA FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 365 CANADA FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 366 CANADA COAGULATION MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 367 CANADA ANTICOAGULATION MONITORING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 368 CANADA ANTICOAGULATION MONITORING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 369 CANADA ANTICOAGULATION MONITORING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 370 CANADA VISCOELASTIC COAGULATION MONITORING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY METHOD, 2018-2032 (USD THOUSAND)

TABLE 371 CANADA DRUG-OF-ABUSE (DOA) TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 372 CANADA DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 373 CANADA DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 374 CANADA DOA ANALYZERS MONITORING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 375 CANADA RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 376 CANADA RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 377 CANADA RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 378 CANADA URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 379 CANADA URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 380 CANADA URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 381 CANADA CHOLESTEROL TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 382 CANADA CHOLESTEROL TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 383 CANADA CHOLESTEROL TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 384 CANADA INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 385 CANADA INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 386 CANADA INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 387 CANADA FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 388 CANADA FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 389 CANADA FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 390 CANADA POINT-OF-CARE-TESTING (POCT) MARKET, BY PLATFORM, 2018-2032 (USD THOUSAND)

TABLE 391 CANADA POINT-OF-CARE-TESTING (POCT) MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 392 CANADA INFECTIOUS DISEASES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 393 CANADA POINT-OF-CARE-TESTING (POCT) MARKET, BY PRESCRIPTION MODE, 2018-2032 (USD THOUSAND)

TABLE 394 CANADA POINT-OF-CARE-TESTING (POCT) MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 395 CANADA HOSPITALS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 396 CANADA PRIVATE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY LEVEL, 2018-2032 (USD THOUSAND)

TABLE 397 CANADA PUBLIC IN POINT-OF-CARE-TESTING (POCT) MARKET, BY LEVEL, 2018-2032 (USD THOUSAND)

TABLE 398 CANADA POINT-OF-CARE-TESTING (POCT) MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 399 MEXICO POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 400 MEXICO POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 401 MEXICO POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 402 MEXICO GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 403 MEXICO GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 404 MEXICO GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 405 MEXICO INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 406 MEXICO INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 407 MEXICO INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 408 MEXICO HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 409 MEXICO HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 410 MEXICO HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 411 MEXICO SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 412 MEXICO SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 413 MEXICO SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 414 MEXICO HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 415 MEXICO HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 416 MEXICO HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 417 MEXICO INFLUENZA TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 418 MEXICO TRADITIONAL DIAGNOSTIC TEST IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 419 MEXICO TRADITIONAL DIAGNOSTIC TEST IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 420 MEXICO TRADITIONAL DIAGNOSTIC TEST IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 421 MEXICO MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 422 MEXICO MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 423 MEXICO MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 424 MEXICO CARDIOMETABOLIC MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 425 MEXICO POC ANALYZER IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 426 MEXICO POC ANALYZER IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 427 MEXICO CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 428 MEXICO CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 429 MEXICO CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 430 MEXICO BLOOD GAS/ELECTROLYTE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 431 MEXICO BLOOD GAS/ELECTROLYTE TESTING CONSUMABLES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 432 MEXICO BLOOD GAS/ELECTROLYTE TESTING CONSUMABLES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 433 MEXICO BLOOD GAS/ELECTROLYTE TESTING CONSUMABLES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 434 MEXICO BLOOD GAS/ELECTROLYTE TESTING INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 435 MEXICO PORTABLE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 436 MEXICO PORTABLE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 437 MEXICO PORTABLE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 438 MEXICO BENCHTOP IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 439 MEXICO BENCHTOP IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 440 MEXICO BENCHTOP IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 441 MEXICO HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 442 MEXICO HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 443 MEXICO HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 444 MEXICO ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 445 MEXICO ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 446 MEXICO ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 447 MEXICO PREGNANCY AND FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 448 MEXICO PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 449 MEXICO PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 450 MEXICO PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 451 MEXICO FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 452 MEXICO FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 453 MEXICO FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 454 MEXICO COAGULATION MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 455 MEXICO ANTICOAGULATION MONITORING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 456 MEXICO ANTICOAGULATION MONITORING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 457 MEXICO ANTICOAGULATION MONITORING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 458 MEXICO VISCOELASTIC COAGULATION MONITORING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY METHOD, 2018-2032 (USD THOUSAND)

TABLE 459 MEXICO DRUG-OF-ABUSE (DOA) TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 460 MEXICO DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 461 MEXICO DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 462 MEXICO DOA ANALYZERS MONITORING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 463 MEXICO RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 464 MEXICO RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 465 MEXICO RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 466 MEXICO URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 467 MEXICO URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 468 MEXICO URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 469 MEXICO CHOLESTEROL TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 470 MEXICO CHOLESTEROL TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 471 MEXICO CHOLESTEROL TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 472 MEXICO INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 473 MEXICO INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 474 MEXICO INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 475 MEXICO FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 476 MEXICO FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 477 MEXICO FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 478 MEXICO POINT-OF-CARE-TESTING (POCT) MARKET, BY PLATFORM, 2018-2032 (USD THOUSAND)

TABLE 479 MEXICO POINT-OF-CARE-TESTING (POCT) MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 480 MEXICO INFECTIOUS DISEASES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 481 MEXICO POINT-OF-CARE-TESTING (POCT) MARKET, BY PRESCRIPTION MODE, 2018-2032 (USD THOUSAND)

TABLE 482 MEXICO POINT-OF-CARE-TESTING (POCT) MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 483 MEXICO HOSPITALS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 484 MEXICO PRIVATE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY LEVEL, 2018-2032 (USD THOUSAND)

TABLE 485 MEXICO PUBLIC IN POINT-OF-CARE-TESTING (POCT) MARKET, BY LEVEL, 2018-2032 (USD THOUSAND)

TABLE 486 MEXICO POINT-OF-CARE-TESTING (POCT) MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

List of Figure

FIGURE 1 NORTH AMERICA POINT-OF-CARE-TESTING (POCT) MARKET: SEGMENTATION

FIGURE 2 NORTH AMERICA POINT-OF-CARE-TESTING (POCT) MARKET: DATA TRIANGULATION

FIGURE 3 NORTH AMERICA POINT-OF-CARE-TESTING (POCT) MARKET: DROC ANALYSIS

FIGURE 4 NORTH AMERICA POINT-OF-CARE-TESTING (POCT) MARKET: REGIONAL MARKET ANALYSIS

FIGURE 5 NORTH AMERICA POINT-OF-CARE-TESTING (POCT) MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 NORTH AMERICA POINT-OF-CARE-TESTING (POCT) MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 NORTH AMERICA POINT-OF-CARE-TESTING (POCT) MARKET: DBMR MARKET POSITION GRID

FIGURE 8 NORTH AMERICA POINT-OF-CARE-TESTING (POCT) MARKET: MARKET END USER COVERAGE GRID

FIGURE 9 NORTH AMERICA POINT-OF-CARE-TESTING (POCT) MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 NORTH AMERICA POINT-OF-CARE-TESTING (POCT) MARKET: SEGMENTATION

FIGURE 11 RISING USE OF POC TESTING IN HEALTHCARE FACILITIES IS EXPECTED TO DRIVE THE GROWTH OF NORTH AMERICA POINT-OF-CARE-TESTING (POCT) MARKET FROM 2025 TO 2032

FIGURE 12 THE GLUCOSE MONITORING PRODUCTS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA POINT-OF-CARE-TESTING (POCT) MARKET IN 2025 - 2032

FIGURE 13 NORTH AMERICA POINT-OF-CARE-TESTING (POCT) MARKET EXECUTIVE SUMMARY

FIGURE 14 STRATEGIC DECISIONS

FIGURE 15 TWELVE SEGMENTS COMPRISE THE NORTH AMERICA POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE (2024)

FIGURE 16 DROC ANALYSIS

FIGURE 17 NORTH AMERICA POINT-OF-CARE-TESTING (POCT) MARKET: BY PRODUCT TYPE, 2024

FIGURE 18 NORTH AMERICA POINT-OF-CARE-TESTING (POCT) MARKET: BY PRODUCT TYPE, 2025-2032 (USD THOUSAND)

FIGURE 19 NORTH AMERICA POINT-OF-CARE-TESTING (POCT) MARKET: BY PRODUCT TYPE, CAGR (2025-2032)

FIGURE 20 NORTH AMERICA POINT-OF-CARE-TESTING (POCT) MARKET: BY PRODUCT TYPE, LIFELINE CURVE

FIGURE 21 NORTH AMERICA POINT-OF-CARE TESTING (POCT) MARKET: BY PRESCRIPTION MODE, 2024

FIGURE 22 NORTH AMERICA POINT-OF-CARE TESTING (POCT) MARKET: BY PRESCRIPTION MODE, 2025 TO 2032 (USD THOUSAND)

FIGURE 23 NORTH AMERICA POINT-OF-CARE TESTING (POCT) MARKET: BY PRESCRIPTION MODE, CAGR (2025- 2032)

FIGURE 24 NORTH AMERICA POINT-OF-CARE TESTING (POCT) MARKET: BY PRESCRIPTION MODE, LIFELINE CURVE

FIGURE 25 NORTH AMERICA POINT-OF-CARE TESTING (POCT) MARKET: BY PLATFORM, 2024

FIGURE 26 NORTH AMERICA POINT-OF-CARE TESTING (POCT) MARKET: BY PLATFORM, 2025 TO 2032 (USD THOUSAND)

FIGURE 27 NORTH AMERICA POINT-OF-CARE TESTING (POCT) MARKET: BY PLATFORM, CAGR (2025- 2032)

FIGURE 28 NORTH AMERICA POINT-OF-CARE TESTING (POCT) MARKET: BY PLATFORM, LIFELINE CURVE

FIGURE 29 NORTH AMERICA POINT-OF-CARE TESTING (POCT) MARKET: BY APPLICATION, 2024

FIGURE 30 NORTH AMERICA POINT-OF-CARE TESTING (POCT) MARKET: BY APPLICATION, 2025 TO 2032 (USD THOUSAND)

FIGURE 31 NORTH AMERICA POINT-OF-CARE TESTING (POCT) MARKET: BY APPLICATION, CAGR (2025- 2032)

FIGURE 32 NORTH AMERICA POINT-OF-CARE TESTING (POCT) MARKET: BY APPLICATION, LIFELINE CURVE

FIGURE 33 NORTH AMERICA POINT-OF-CARE TESTING (POCT) MARKET: BY END USER, 2024

FIGURE 34 NORTH AMERICA POINT-OF-CARE TESTING (POCT) MARKET: BY END USER, 2025 TO 2032 (USD THOUSAND)

FIGURE 35 NORTH AMERICA POINT-OF-CARE TESTING (POCT) MARKET: BY END USER, CAGR (2025- 2032)

FIGURE 36 NORTH AMERICA POINT-OF-CARE TESTING (POCT) MARKET: BY END USER, LIFELINE CURVE

FIGURE 37 NORTH AMERICA POINT-OF-CARE TESTING (POCT) MARKET: BY DISTRIBUTION CHANNEL, 2024

FIGURE 38 NORTH AMERICA POINT-OF-CARE TESTING (POCT) MARKET: BY DISTRIBUTION CHANNEL, 2025 TO 2032 (USD THOUSAND)

FIGURE 39 NORTH AMERICA POINT-OF-CARE TESTING (POCT) MARKET: BY DISTRIBUTION CHANNEL, CAGR (2025- 2032)

FIGURE 40 NORTH AMERICA POINT-OF-CARE TESTING (POCT) MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 41 NORTH AMERICA POINT-OF-CARE-TESTING (POCT) MARKET: SNAPSHOT (2024 )

FIGURE 42 NORTH AMERICA POINT-OF-CARE TESTING (POCT) MARKET: COMPANY SHARE 2024 (%)

View Detailed Information Right Arrow

Research Methodology

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Customization Available

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Frequently Asked Questions

The North America point-of-care testing (POCT) market size was valued at USD 16.29 billion in 2024.
The North America point-of-care testing (POCT) market is to grow at a CAGR of 9.5% during the forecast period of 2025 to 2032.
The North America point-of-care testing (POCT) market is categorized into six notable segments based on product type, platform, application, prescription mode, end user, and distribution channel. On the basis of product type, the market is segmented into glucose monitoring products, infectious disease testing products, cardiometabolic monitoring products, pregnancy and fertility testing products, hematology testing products, coagulation monitoring products, drugs-of-abuse (DOA) testing products, urinalysis testing products, cholesterol testing products, tumor/cancer marker testing products, fecal occult testing products, and others. On the basis of platform, the market is segmented into lateral flow assays/immunochromatography tests, immunoassays, dipsticks, molecular diagnostics, clinical chemistry assays, microfluidics, hematology, and others. On the basis of application, the market is segmented into blood glucose, infectious diseases, vital sign monitoring, cardiac monitoring, coagulation, haematology, Non- Invasive SpO2 monitoring, blood transfusion, Non- Invasive PCO2 monitoring, whole blood analysis, and others. On the basis of prescription mode, the market is segmented into OTC testing and prescription-based testing. On the basis of end user, the market is segmented into hospitals, home care, clinics, laboratories, diagnostic centers, pathology labs, ambulatory surgery centers, elderly care centers, and others. On the basis of distribution channel, the market is segmented into direct tender, retail sales, online sales, and others.
Companies such as F. Hoffmann-La Roche Ltd (Switzerland), Danaher Corporation (U.S.), Siemens Healthineers AG (Germany), BD (Becton, Dickinson and Company) (U.S.), and Abbott (U.S.) are major players in North America point-of-care testing (POCT) market.

Browse Related Pages

Banner
Testimonial
Image
Claudio Rondena Group Business Development & Strategic Marketing Director,
C.O.C Farmaceutici SRL
"This morning we were involved in the first part, the data presentation of MKT analysis, selected abstract from your work. The board team was really impressed and very appreciated, as well."
Image
David Manning - Thermo Fisher Scientific Director, Global Strategic Accounts,
Dear Ricky, I want to thank you for the excellent market analysis (LIMS INSTALLED BASE DATA) that you and your team delivered, especially end of year on short notice. Sachin and Shraddha captured the requirements, determined their path forward and executed quickly.
You, Sachin and Shraddha have been a pleasure to work with – very responsive, professional and thorough. Your work is much appreciated.
Image
Manager - Market Analytics, Uriah D. Avila - Zeus Polymer Solutions
Thank you for all the assistance and the level of detail in the market report. We are very pleased with the results and the customization. We would like to continue to do business.
Image
Business Development Manager, (Pharmaceuticals Partner for Nasal Sprays) | Renaissance Lakewood LLC
DBMR was attentive and engaged while discussing the Global Nasal Spray Market. They understood what we were looking for and was able to provide some examples from the report as requested. DBMR Service team has been responsive as needed. Depending on what my colleagues were looking for, I will recommend your services and would be happy to stay connected in case we can utilize your research in the future.
Image
Business Intelligence and Analytics, Ipsen Biopharm Limited

We are impressed by the CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT report - so a BIG thanks to you colleagues.

Image
Competition Analyst, Basler Web

I just wanted to share a quick note and let you know that you guys did a really good job. I’m glad I decided to work with you. I shall continue being associated with your company as long as we have market intelligence needs.

Image
Marketing Director, Buhler Group

It was indeed a good experience, would definitely recommend and come back for future prospects.

Image
COO, A global leader providing Drug Delivery Services

DBMR did an outstanding job on the Global Drug Delivery project, We were extremely impressed by the simple but comprehensive presentation of the study and the quality of work done. This report really helped us to access untapped opportunities across the globe.

Image
Marketing Director, Philips Healthcare

The study was customized to our targets and needs with well-defined milestones. We were impressed by the in-depth customization and inclusion of not only major but also minor players across the globe. The DBMR Market position grid helped us to analyze the market in different dimension which was very helpful for the team to get into the minute details.

Image
Product manager, Fujifilms

Thankful to the team for the amazing coordination, and helping me at the last moment with my presentation. It was indeed a comprehensive report that gave us revenue impacting solution enabling us to plan the right move.

Image
Investor relations, GE Healthcare

Thank you for the report, and addressing our needs in such short time. DBMR has outdone themselves in this project with such short timeframe.

Image
Market Analyst, Medincell

We found the results of this study compelling and will help our organization validate a market we are considering to enter. Thank you for a job well done.

Image
Andrew - Senior Global Marketing Manager, Medtronic (US)

I want to thank you for your help with this report – It’s been very helpful in our business planning and it well organized.

Image
Amarildo - Manager, Global Strategic Alignment MasterCard

We believe the work done by Data Bridge Team for our requirements in the North America Loyalty Management Market was fantastic and would love to continue working with your team moving forward.

Image
Tor Hammer Green Nexus LLc

Thank you for your quick response to this unfortunate circumstance. Please extend my thanks to your reach team. I will be contacting you in the future with further projects

Image
Tommaso Finocchiaro Market Intelligence Specialist Nippon Gasses

I acknowledge the difficulty given by the very short warning for this report, and I think that its quality and your delivering time have been very satisfying. Obviously, as a provider Data Bridge Market Research will be considered as a plus for future needs of Nippon Gases.

Image
Yuki Kopyl (Asian Business Development Department) UENO FOOD TECHNO INDUSTRY, LTD. (JAPAN)

Xylose report was very useful for our team. Thank you very much & hope to work with you again in the future